brodalumab Side Effects
Also known as: Siliq
Analysis of 1,890 adverse event reports submitted to the FDA from 2013 to 2025.
Total Reports
1,890
Death-Related
133
7.0% of reports
Hospitalizations
535
28.3% of reports
Top Indication
Psoriasis
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 133 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 72 |
| PSORIASIS | 11 |
| INTENTIONAL PRODUCT USE ISSUE | 9 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 8 |
| PRODUCT DOSE OMISSION ISSUE | 8 |
| BLOOD PRESSURE INCREASED | 7 |
| PNEUMONIA | 7 |
| FALL | 6 |
| ASTHENIA | 5 |
| COUGH | 5 |
| COVID-19 | 5 |
| DISEASE RECURRENCE | 5 |
| FATIGUE | 5 |
| HEADACHE | 5 |
| HOSPITALISATION | 5 |
| ILLNESS | 5 |
| MALAISE | 5 |
| NEOPLASM MALIGNANT | 5 |
| PRURITUS | 5 |
| RENAL FAILURE | 5 |
Reactions in Hospitalization Reports
Top reactions in 535 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PSORIASIS | 147 |
| HOSPITALISATION | 57 |
| PRODUCT DOSE OMISSION ISSUE | 57 |
| DRUG INEFFECTIVE | 50 |
| ARTHRALGIA | 45 |
| INTENTIONAL PRODUCT USE ISSUE | 45 |
| THERAPY INTERRUPTED | 43 |
| FALL | 41 |
| OFF LABEL USE | 40 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 37 |
| COVID-19 | 33 |
| FATIGUE | 31 |
| CONDITION AGGRAVATED | 30 |
| DISEASE RECURRENCE | 30 |
| HEADACHE | 29 |
| PNEUMONIA | 27 |
| PRURITUS | 27 |
| PAIN IN EXTREMITY | 26 |
| PATIENT DISSATISFACTION WITH TREATMENT | 25 |
| DIARRHOEA | 24 |
Nearby — Related Medications
What the FAERS Data Reveals About brodalumab Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,890 voluntary reports linked to brodalumab and its brand equivalents (Siliq), spanning 2013 through 2025. Of those, 133 (7.0%) listed death as an outcome and 535 (28.3%) involved hospitalization. The most common indication reported alongside adverse events was Psoriasis.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 46% were female and 54% male; age distribution skews toward 45-64, with 646 reports in that bracket. The single most reported reaction is psoriasis with 471 submissions, followed by drug ineffective and arthralgia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.